Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Shares of Merck & Co. (MRK) tumbled Tuesday after the pharmaceutical giant cut its full-year adjusted profit guidance.

Merck Stock Slides on Lowered Adjusted EPS Guidance

Merck & Co. Inc. NYSE: MRK delivered a solid earnings report before the market opened on July 30, 2024. However, the stock was down over 4% in early trading after the company cut its full-year earnings forecast.

Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity

While the top- and bottom-line numbers for Merck (MRK) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key Metrics

Pfizer

Pharmaceutical giants Merck & Co Inc  (NYSE:MRK) and Pfizer Inc (NYSE:PFE) today reported second-quarter results.

Options Traders Blast 2 Pharma Socks After Earnings

Merck (MRK) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $2.16 per share. This compares to loss of $2.06 per share a year ago.

Merck (MRK) Q2 Earnings and Revenues Top Estimates

Merck reported better-than-expected earnings, but the pharmaceutical giant's outlook fell short of expectations.

Merck Posts Stronger-Than-Expected Results, But Outlook Falls Short

Merck & Co Inc's (NYSE:MRK, ETR:6MK) shares rose 1.4% in pre-market trading after reporting higher-than-expected second-quarter results, driven by strong sales of its top-selling cancer drug, Keytruda.  It prompted the group to raise its sales target for 2024, though its 2024 earnings line has been tweaked lower to reflect one-off acquisition charges.

Merck higher pre-market as Q2 sales beat forecasts

Shares of Merck & Co. MRK, +2.01% slipped 0.6% in premarket trading Tuesday, after the drug maker reported second-quarter profit and sales that beat expectations, amid strength in sales of cancer treatment Keytruda, while providing a mixed full-year outlook. The company swung to net income of $5.46 billion, or $2.14 a share, from a loss of $5.98 billion, or $2.35 a share, in the same period a year ago.

Merck beats profit and sales expectations amid Keytruda strength, but provides mixed full-year outlook

Merck & Co posted higher-than-expected second-quarter results on Tuesday on strong growth of its blockbuster cancer immunotherapy Keytruda, the world's best-selling prescription medicine.

Merck second quarter tops Street view on strong Keytruda sales

Merck reported second-quarter revenue and adjusted earnings that topped estimates as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and vaccines portfolios and a new cardiovascular drug.  The pharmaceutical giant also raised its full-year sales forecast to a range of $63.4 billion to $64.4 billion, however it lowered its adjusted profit guidance to between $7.94 and $8.04 per share.

Merck beats earnings expectations -- raises sales outlook on strong demand for top drugs like Keytruda

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Second-Quarter 2024 Financial Results.

Merck Announces Second-Quarter 2024 Financial Results

Both Merck and Pfizer are expected to report their Q2 '24 financial results on Tuesday morning, July 30 '24, before the opening bell. It's time for Pfizer to make hay after the pandemic spike, when the stock jumped from $30 in 2020 to $60 in late '21. Today, Merck is really all about Keytruda and what the pharma giant can squeeze from it, as it awaits further pipeline development.

Pfizer And Merck's Earnings Previews: Uncorrelated To Big Tech, And Growth Styles

Germany's Merck on Friday further its forecast for the group and said it now expects net sales to be between 20.7 billion euros ($22.49 billion) and 22.1 billion euros for 2024.

Germany's Merck raises 2024 sales forecast

Merck (NYSE: MRK) will report its Q2 2024 results on Tuesday, July 30. We expect the company to post revenue of $15.9 billion and adjusted earnings of $2.20, slightly ahead of the street estimates.

Is An Earnings Beat In The Cards For Merck Stock?

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Advanced Bladder Cancer.

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.

Countdown to Merck (MRK) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

Merck & Co will announce Q2 2024 earnings on July 30th. Merck's share price has risen 65% in the past 3 years, driven by the success of Keytruda, the world's best-selling drug. Keytruda revenues were up 25% year-on-year in Q1 2024, contributing nearly 45% of Merck's total revenues last quarter.

Merck Q2 Earnings Preview: We Need To Talk About Keytruda's LOE

Amgen

Gilead Sciences

International Paper

Iron Mountain

Labcorp Holdings Inc

Super Micro Computer

No one knows when the next S&P 500 crash will hit. But everyone should know which stocks to watch out for.

Look Out Below If You Still Own 7 Stocks When The Crash Comes

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Fourth-Quarter 2024 Dividend.

Merck Announces Fourth-Quarter 2024 Dividend

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports second-quarter 2024 earnings.

Should You Buy, Sell or Hold Merck (MRK) Ahead of Q2 Earnings?

Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (MRK) Earnings Expected to Grow: Should You Buy?

Merck's stock has surged 16.8% year-to-date, outpacing the Dow Jones. Keytruda remains a key growth driver, but patent expiration looms in 2028.

Billionaires Are Loading Up on This Surging Dow Stock. Should You?

Merck said on Tuesday its respiratory syncytial virus (RSV) drug met the safety and efficacy goals in a mid- to late- stage study testing it in infants.

Merck's RSV drug meets main goals of mid-to-late stage trial

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK--Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational RSV Preventative Monoclonal Antibody for Infants.

Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants

If you think S&P 500 second-quarter earnings season is only about Big Tech stocks — you're only partly right.

News for Merck Stock (MRK)